146 related articles for article (PubMed ID: 6225476)
1. Current status of high dose progestin treatment in advanced breast cancer.
Mattsson W
Breast Cancer Res Treat; 1983; 3(2):231-5. PubMed ID: 6225476
[TBL] [Abstract][Full Text] [Related]
2. Oral plus intramuscular medroxyprogesterone acetate (high dose Farlutal) in advanced breast cancer.
Ngelangel CA; Jimenez MV; Villalon AH; Agustin BM
Southeast Asian J Trop Med Public Health; 1985 Dec; 16(4):634-7. PubMed ID: 2940689
[TBL] [Abstract][Full Text] [Related]
3. The role of progestins in the treatment of breast cancer.
Blumenschein GR
Semin Oncol; 1983 Dec; 10(4 Suppl 4):7-10. PubMed ID: 6230722
[TBL] [Abstract][Full Text] [Related]
4. The pharmacokinetics of high-dose medroxyprogesterone acetate (MPA) in the therapy of advanced breast cancer.
Blossey HC; Bartsch HH; Kanne D; Koebberling J; Nagel GA
Cancer Chemother Pharmacol; 1982; 8(1):77-81. PubMed ID: 6212156
[No Abstract] [Full Text] [Related]
5. Randomized trial of low- versus high-dose medroxyprogesterone acetate in the induction treatment of postmenopausal patients with advanced breast cancer.
Cavalli F; Goldhirsch A; Jungi F; Martz G; MermillodB ; Alberto P
J Clin Oncol; 1984 May; 2(5):414-9. PubMed ID: 6233398
[TBL] [Abstract][Full Text] [Related]
6. High progesterone receptor concentration in a variant of the ZR-75-1 human breast cancer cell line adapted to growth in oestrogen free conditions.
van den Berg HW; Martin J; Lynch M
Br J Cancer; 1990 Apr; 61(4):504-7. PubMed ID: 2139575
[TBL] [Abstract][Full Text] [Related]
7. Oral high-dose progestins as treatment for advanced breast cancer.
Lundgren S; Kvinnsland S; Utaaker E
Acta Oncol; 1989; 28(6):811-6. PubMed ID: 2532917
[TBL] [Abstract][Full Text] [Related]
8. Combination therapy with progestins and tamoxifen in advanced breast cancer: A preliminary report.
Trodella L; Ausilli-Cefaro GP; Turriziani A; Saccheri S; Venturo I; Minotti G
Am J Clin Oncol; 1982 Oct; 5(5):495-9. PubMed ID: 6217741
[No Abstract] [Full Text] [Related]
9. High-dose medroxyprogesterone acetate in advanced breast cancer. Clinical and pharmacokinetic study with a combined oral and intramuscular regimen.
Becher R; Miller AA; Höffken K; Gerhold U; Hirche H; Schmidt CG
Cancer; 1989 May; 63(10):1938-43. PubMed ID: 2522811
[TBL] [Abstract][Full Text] [Related]
10. [Clinical investigation of oral high-dose medroxyprogesterone acetate (MPA) in advanced breast cancer--double-blind controlled study: Japanese Group for MPA Treatment of Breast Cancer].
Izuo M; Tominaga T; Yoshida M; Nomura Y; Abe O; Enomoto K; Kubo K; Takatani O
Gan No Rinsho; 1985 May; 31(5):487-93. PubMed ID: 3160869
[TBL] [Abstract][Full Text] [Related]
11. High-dose medroxyprogesterone acetate (MPA) in advanced epithelial ovarian cancer resistant to first- or second-line chemotherapy.
Mangioni C; Franceschi S; La Vecchia C; D'Incalci M
Gynecol Oncol; 1981 Dec; 12(3):314-8. PubMed ID: 6458544
[No Abstract] [Full Text] [Related]
12. The effects of sequential treatment with ethynyloestradiol and medroxyprogesterone acetate on oestrogen and progestogen receptors in breast cancer.
Ghilchik M; Shaikh NA; Beranek PA; Reed MJ; Braunsberg H
J Steroid Biochem; 1989; 34(1-6):403-5. PubMed ID: 2533948
[TBL] [Abstract][Full Text] [Related]
13. Influence of tamoxifen-medroxyprogesterone sequential therapy on estrogen and progesterone receptor contents of breast cancer.
Noguchi S; Yamamoto H; Inaji H; Imaoka S; Koyama H
Jpn J Cancer Res; 1989 Mar; 80(3):244-8. PubMed ID: 2524460
[TBL] [Abstract][Full Text] [Related]
14. Current status of high-dose progestins in breast cancer.
Abrams JS; Parnes H; Aisner J
Semin Oncol; 1990 Dec; 17(6 Suppl 9):68-72. PubMed ID: 2148027
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic and pharmacodynamic basis for the treatment of metastatic breast cancer with high-dose medroxyprogesterone acetate.
Blossey HC; Wander HE; Koebberling J; Nagel GA
Cancer; 1984 Sep; 54(6 Suppl):1208-15. PubMed ID: 6088020
[TBL] [Abstract][Full Text] [Related]
16. Rectal administration of medroxyprogesterone acetate in cancer patients: a pharmacokinetic study.
Pannuti F; Vancini B; Comparsi R; Strocchi E; Camaggi CM
Cancer Treat Rep; 1986 Jul; 70(7):937-8. PubMed ID: 2941143
[No Abstract] [Full Text] [Related]
17. [High dose medroxyprogesterone acetate in metastatic breast cancer. Comparative clinical, pharmacokinetic and pharmacodynamic data of different forms of administration].
Blossey HC; Wander HE; Nagel GA; Köbberling J; Kleeberg U
Onkologie; 1982 Aug; 5 Suppl():13-6. PubMed ID: 6215599
[TBL] [Abstract][Full Text] [Related]
18. Cyclic and sequential therapy with tamoxifen and medroxyprogesterone acetate in metastatic breast cancer.
Nemoto T; Patel JK; Rosner D; Dao TL; Halvorson H
J Surg Oncol; 1989 Aug; 41(4):226-9. PubMed ID: 2526907
[TBL] [Abstract][Full Text] [Related]
19. Progestational agents in advanced breast cancer: an overview.
Haller DG; Glick JH
Semin Oncol; 1986 Dec; 13(4 Suppl 4):2-8. PubMed ID: 3026051
[TBL] [Abstract][Full Text] [Related]
20. Oral route administration of medroxyprogesterone acetate (MAP) at high doses in the treatment of advanced breast cancer: clinical results.
Guarnieri A; Tucci E; D'Aniello C; Carli A; Mariani L; De Stefano A; Nardi P
Chemioterapia; 1984 Oct; 3(5):320-3. PubMed ID: 6241848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
